26.06.2015 • News

ADC Therapeutics Appoints Chris Martin as CEO

ADC Therapeutics announced the appointment of Dr Chris Martin as its CEO. Dr Martin was co-founder of Spirogen and its CEO leading up to the sale of Spirogen to MedImmune, the global biologics research and development arm of AstraZeneca in October 2013. He continued as CEO of Spirogen, and became both a member of Medimmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. He will continue to advise Medimmune as a consultant.
Dr. Martin played an important role in the formation of ADC Therapeutics in 2012, and has served on its board of directors since its founding. He replaces Michael Forer, CEO of the Company since its formation, who becomes vice chairman of ADC Therapeutics, and will continue to work with the company as executive vice president.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Top-Feature

most read